Cellectar Biosciences
CLRB
26 hedge funds and large institutions have $23.9M invested in Cellectar Biosciences in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
521% more capital invested
Capital invested by funds: $3.85M → $23.9M (+$20M)
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
37% more funds holding
Funds holding: 19 → 26 (+7)
1.84% more ownership
Funds ownership: 0.5% → 2.34% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.35M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.07M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$1.03M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$885K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$762K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$57K |
| 2 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$31.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.66K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$149 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$74 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $44 | +$74 | +1 | New |
|
|
27
Renaissance Technologies
New York
| – | -$57K | -723 | Closed |
|
|
28
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
| – | -$31.7K | -400 | Closed |
|
CLRB Hedge Fund Activity: Q4 2023 in Review
26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2023, worth a combined $23.9M — up 521% from $3.85M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CLRB positions and 2 closed out — a net gain of 7 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.35M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $57K sold.
- 26 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2023, up from 19 in Q3 2023.
- Funds reported $23.9M of Cellectar Biosciences stock for Q4 2023, up 521% quarter-over-quarter.
- 9 funds opened new Cellectar Biosciences positions in Q4 2023 and 2 closed out, a net change of +7 holders.
- The largest Cellectar Biosciences buyer in Q4 2023 was Nantahala Capital Management, an estimated $3.35M added.
- The largest Cellectar Biosciences seller in Q4 2023 was Renaissance Technologies, an estimated $57K sold.
Based on aggregated 13F filings for Q4 2023.